ELVN · Enliven Therapeutics Inc.
-
-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US29337E1029 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 2B |
|---|---|
| PE Ratio | None |
| Target Price | 46.4286 |
| Beta | 1.06 |
| Dividend Yield | None |
ABOUT
Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Learn More